{"entity":{"id":"nct04586478","kind":"trial","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","aka":[],"tldr":"A phase 2 trial of single dose of CNCT19 in non-Hodgkin lymphoma, run by Juventas Cell Therapy Ltd., now recruiting.","summary":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT04586478 by Juventas Cell Therapy Ltd., with 60 participants planned, started 2020-10-26 and due to reach its primary completion in 2024-03-30. Interventions recorded: single dose of CNCT19.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04586478","url":"https://clinicaltrials.gov/study/NCT04586478"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["inaticabtagene-autoleucel"],"companies":["juventas-cell-therapy"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04586478","phase":"2","setting":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","sponsor":"Juventas Cell Therapy Ltd.","started":"2020-10-26","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04586478/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/"}],"company":[{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","route":"/companies/juventas-cell-therapy/"}]}}